Reducing Available Soluble β-Amyloid Prevents Progression of Cerebral Amyloid Angiopathy in Transgenic Mice

Differential Effects between  -Secretase Inhibitors and Modulators on Cognitive Function in Amyloid Precursor Protein-Transgenic and Nontransgenic Mice

(2012) Y. Mitani et al.   JOURNAL OF NEUROSCIENCE

Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: Recommendations from the Alzheimer’s Association Research Roundtable Workgroup

(2011) Reisa A. Sperling et al.   Alzheimers & Dementia

What the halted phase III γ-secretase inhibitor trial may (or may not) be telling us

(2011) Nina F. Schor   ANNALS OF NEUROLOGY

Existing plaques and neuritic abnormalities in APP:PS1 mice are not affected by administration of the gamma-secretase inhibitor LY-411575

(2009) Monica Garcia-Alloza et al.   Molecular Neurodegeneration

Cytoplasmic gelsolin increases mitochondrial activity and reduces Aβ burden in a mouse model of Alzheimer's disease

(2009) Desiree Antequera et al.   NEUROBIOLOGY OF DISEASE

A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease

(2009) S. Salloway et al.   NEUROLOGY

Consequence of Aβ immunization on the vasculature of human Alzheimer's disease brain

(2008) D. Boche et al.   BRAIN

Immunotherapy Reduces Vascular Amyloid-  in PDAPP Mice

(2008) S. Schroeter et al.   JOURNAL OF NEUROSCIENCE

Dynamics of A  Turnover and Deposition in Different  -Amyloid Precursor Protein Transgenic Mouse Models Following  -Secretase Inhibition

(2008) D. Abramowski et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Functional gamma-secretase inhibitors reduce beta-amyloid peptide levels in brain

(2003) H. F. Dovey et al.   JOURNAL OF NEUROCHEMISTRY